Bluebird Bio Inc (BLUE)

[mrsmeg3]

Signs of intelligent life here, so let me ask, good buy at these levels? Every other forum has people shouting the end is near, despite 3 approved therapies, patients, hospital partners, and revenue (albeit small) starting. What say you?

[georgie18]

Earnings call at 5PM...for NVIDIA...🥳

[Spuds McKenz66]

cool forgot about that , ya need a good day tomorrow push us over 70 BLUE

[georgie18]

Yes considering a red day so far...NVIDIA earning in the A/H...could turn the market either way...🥳

[Spuds McKenz66]

holding up nicely BLUE

[Monksdream]

BLUE new 52 week low and headed for the noncompliant list

[Spuds McKenz66]

ok good ya thats me BLUE :)

[georgie18]

13,900 showing at 639...5000 showing at 635...on my L2...🥳

[Spuds McKenz66]

I will buy more through the day will see if those orders show BLUE

[Spuds McKenz66]

rock and roll BLUES brothers

[Spuds McKenz66]

I hit the ask and bought a total of 21700 shares at approx. 7.30 AM ... BLUE

[Spuds McKenz66]

bought 14k at 7.30AM not showing my buy order bought 5k at 7.33AM not showing my buy order again BLUE

[georgie18]

Gave off some strong trades...last time in March /April...Think it will do it again...🥳

[novicetrader]

BLUE will have it's day someday. Have liked this one for a long time

[georgie18]

Nice...🥳

[Spuds McKenz66]

started buying BLUE

[Monksdream]

You love it at 50 and you love it at 30

[georgie18]

That’s why I am loading…love buying bottoms with Bullish Candles…Will load up or down…🥳

[Monksdream]

BLUE new 52/week low

[Monksdream]

BLUE new 52=week low

[georgie18]

BLUE...69... https://schrts.co/eiUgsPhA ...🥳...Bullish Harami Cross...Reversal Pattern to the Upside...50% range drop from last spike...Was a Great Trader last time around...Scaling in here...

[Moose412]

Ain't no stopping this train.

[Monksdream]

BLUE new 52 low

[Monksdream]

BLUE new 52 week low

[Monksdream]

BLUE new 52 week low

[Monksdream]

BLUE under $2

[stocksrising]

Cool, have a gr8 wkd too!!!

[Moose412]

Buys clearing sales at 2:1 on close today. Have a relaxing weekend!

[stocksrising]

???
Although they say rev/cash won’t be affected, Nasdaq and certain requirements may cause RS, other shareholder issues, NO??
I will reload once filed!!!

On March 26, 2024, bluebird announced that it will restate its consolidated financial statements for the first three quarters and full-year 2022, as well as the first three quarters of 2023. As a result, the Company’s Annual Report Form 10-K for 2023 and its Q1 2024 Form 10-Q have been delayed. The Company is continuing to work expeditiously to complete these filings. Consistent with previous updates, the restatement is not expected to impact the Company’s cash position or revenue. Mr. Sterling will transition to oversee the restatement process upon his start date.

[Moose412]

I have arguments.

[stocksrising]

Not until K/q’s submitted to sec.gov
This management is not trust worthy!!! Yet!!!

[Moose412]

Seemed like a good day to buy the dip.

[stocksrising]

I encourage both of you folks to send email to blue IR/PR for update regarding financials …Funds won’t buy until compliant!!! ( prob won’t get answer, but we have no other means in which to ‘understand the delay better’)

[e-mail]

Hi Courtney,
When can we expect the 10k/Q's to be filed with SEC/Edgar???
Respectfully,
Shareholder

[stocksrising]

Having been a Long Term Bull, I’m afraid management’s bravado and arrogance has caused many investors( institutional & retail) to flee the ticker!! Until they can properly file their 10K/Q’s, funds and investors will wait it out around this $1 mark..the problems that could/will arise are:
Nasdaq requirements and a ‘going concern’ in their K/Q’s when/if filed….i will add to my sizable position( north of 150k shrs in various accts) once Fins published …would not be shocked with mgmt R/S shares and do another Cap raise!! We need insider buys to feel more secure and believe in mgmts long term goals and targets/estimates..GLTA

[novicetrader]

Been sticking to the higher priced stocks this year(after being bitten badly by the inexpensive tickers for sometime, lol).BLUE is one of the few exceptions that I've let myself into. Waiting for this to shoot above the psychological $1 mark, hopefully soon.Good luck to all of us here.

[Moose412]

That's a nice average - beats mine by a lot!! I hope you're into the long-term.

[novicetrader]

BLUE(0.973) looking good, volume/price spiked yesterday & it's been holding onto those gains today. Should be getting past the dollar mark soon. Prefer a nice steady move rather than a quick pop. Watching closely, my present avg 1.15.

[Moose412]

Seriously? What does this have to do with the actual company?

[johnhancoque]

What is Naked Short Selling?
Before we get into Naked Short Selling let’s understand the basic premises around short selling.
Short selling is the sale of a security that is not owned by the seller.
The motivation for short selling is an investor's belief that a stock's price will decline, enabling the short seller to buy the stock back in the future at a lower price and make a profit.
Normally, when one short sells a stock, their broker will lend them the shares to sell. The loaned stock will come from the broker's own inventory, from another one of the firm's customers, or from another brokerage firm. The shares are sold and the proceeds are credited to the short seller's account.
As payment for borrowing the shares, the short seller is charged a fee, quoted as an annualized percentage of the value of the loaned securities - i.e. a borrower of a stock with a 5% stock borrow rate will be charged $5 per year for every $100 of stock borrowed. Stock borrow rates change daily based in large part on the supply and demand to borrow that particular stock.
If the number of shares available to borrow is in short supply and/or great demand (which is often the case in highly shorted stocks), finding shares to borrow can be difficult and expensive.
A frequently asked question and outlined in our FAQ’s but let’s look at naked short selling from various perspectives.
How does naked short selling effect the stock market?
When a seller "naked short sells a stock" they do not own the shares they are selling and therefore are selling artificial shares. This is like counterfeiting a stock. This process creates an obvious unfair advantage to the seller and an imbalance in the market as the sell side is now increased with more shares – many of which are counterfeit. There is a time limit on how long the seller can sell these shares and be naked on the trade and the time limit is 3 days. This is where the RegSho rules come in and the data we track. If the sellers broker-dealer has not located a borrow to cover this short trade within 3 days they will need to purchase back the shares they have sold on the open market. This process is referred to as a "Buy In".
"When it comes to illicit short selling, the shorts win over 90% of the time"Naked Short – A license to steal?
Naked short selling is yet another creation of the securities industry and is in essence nothing more than a license to create counterfeit shares. When you are inflating the amount of stock that is outstanding in a company, this is considered counterfeiting. The rules justify the practice by saying it helps create smooth, efficient and orderly markets. Same stuff we have heard countless times around high-frequency trading, but in reality we believe this practice leads to shady characters creating unlimited supplies of counterfeit stocks which in turn results in your investment continuing to decline and you wondering why?
I am sure you here because you are a shareholder in a company that just continues to go down, and you have no idea why. Nothing material has happened but the trading doesn’t make any sense. We hear it all the times. Most CEO’s don’t even understand, and are baffled. The worst part is, good luck getting anyone to listen! There is a major epidemic going on right now with naked short selling right now.
It's funny when we hear CEO's say , I will just buy all the shares up and own the whole O/S and they wont be able to short me anymore. Really?
Read about: Global Links Corporation and see what happened when Robert Simpson purchased 100% of Global Link’s 1,158,064 shares. Then you will truly understand how the system is rigged. Back to counterfeiting…

[Moose412]

We've already covered my query of your bearish to bullish flip a few months back; given the content of these posts and the time frame ($20, $18, $10, $100!), you are stead-fast super-bullish, contrary to your post and response from....February?, questioning experience and why bullish. Not to be rude, just wondering where your aces are. All I've got is 4 chips, a chair, and a belief in two things: Coincidence and Einmal ist Keinmal (Once is insignificant). I have other things, too - like substantial recognized losses, as well as substantial unrealized losses here and elsewhere. I have a bit more in our pocket that may be worth all the rest - I have a feeling that Skysona and the associated data set may hold incredible value for addressing both Alzheimers and Substance Abuse/Addiction.

I'm looking for more content like a blind man who can feel the sun. You're the only moderator. Posts should be relevant to the substance of the company - not potshots.

[stocksrising]

I Appreciate your concern for my frustrations with Mgmt, I’m use to IT seeing I’ve been investing for 53 years, took 2 companies public and graduated from a top 10 business school, and worked on Wall Street ( major IB firms) in the 80’s/90’s :)…and now retired…

However, I agree with your assertion about FDA/SEC, so we are on same page my friend..

My guess it got approved without a committee of KOL’s/Panel , etc based on the ‘earlier version’ and the changes made( that allowed for approval)

Adverse Reactions
The most common adverse reactions ≥
Grade 3 (incidence ≥ 20%) were stomatitis, thrombocytopenia,
neutropenia, febrile neutropenia, anemia, and leukopenia.
Three patients died during LYFGENIA clinical trials; one from sudden cardiac death due to underlying disease and two from acute myeloid leukemia who were treated with an….

“earlier version of LYFGENIA using a different manufacturing process and transplant procedure” (Study 1, Group A).

As you are aware, many New cell therapies have a ‘boxed warning’ that would scare the Bjesus out of a patient, but tell that to a sickle cell person and they’ll take the risk to live a ‘normal’ life vs. the The Consequences!

The fact they got Payers that cover Millions of folks is impressive, so 2nd half should provide tremendous revenue growth, we just need them to stretch cash run way ( thru better controls) and get the contract Mfg/lease issue behind them!!
File the K/ and Q’s and ambulance chasers will disappear..GLTA

[Moose412]

I'm sorry you're frustrated, it is understandable. What is NOT understandable is why the FDA would approve lovo-cel/Lyfgenia with a Black Box warning. As I have already said, if the BB warning holds merit, the hold should never have been lifted in the first place. To be clear, THAT is where I think you should focus your frustrations - the hit job by the FDA. Any lawyers worth their salt aren't involved in this class action. IMHO.

The SEC should absolutely be investigating Dec 8 2023 stock action on CRSP and BLUE with special deference to the FDA.

[stocksrising]

Not a bad gig if you can find one like Blueballs likes to handout!! (New CFO)

(a) Base Salary. The Executive's
“base salary rate shall be $500,000 per year”

. The Executive's base salary shall be re-determined annually
by the Board or the Compensation Committee of the Board of Directors (the "Compensation Committee"). The annual base salary rate in effect at any given time is referred to herein as "Base Salary." The Executive's Base Salary shall be payable in a manner that is consistent with the Company's usual payroll practices for senior executives.
(b) Incentive Compensation. The Executive shall be eligible to receive cash incentive compensation as determined by the Board or the
Compensation Committee from time to time. The Executive's target annual incentive compensation shall be forty five percent (45%) of their Base Salary, although any the actual incentive compensation amount shall be discretionary.

(c) Equity. The Executive shall be granted: i)

an “option to purchase 300,000 shares of the Common Stock of the Company (the upuon), ii) 100,000 restricted stock units (the "RSUs"), and iii) 50,000 performance-based restricted stock units, The Option shall shares (the "PRSUs"),

which PRSUs shall be granted subject to stockholder approval of an increase to the aggregate shares authorized for issuance under the Company's 2023 Incentive Award Plan at the Company's 2024 annual meeting of stockholders. The Option shall have an exercise price equal to the closing price of the Company's common stock on the NASDAQ Global Select Market on the date of grant (the "Grant Date"), and 25% shall vest and become exercisable on the first anniversary of the Grant Date, and in equal monthly installments over the following three years, provided the Executive continues his employment through the applicate vesting date, and shall be memorialized in an Incentive Stock Option Agreement pursuant to the Company's 2021 Inducement Plan. The RSUs shall vest as follows, provided the Executive continues his employment through the applicable vesting date: 25% on the first anniversary of the Grant Date, and in three equal annual installments for the following three years on the anniversaries of the Grant Date, and shall be memorialized in a Restricted Stock Unit Agreement pursuant to the Company's 2021 Inducement Plan. The PRSUs shall vest, to the extent earned based on the achievement of certain total shareholder return performance metrics, on the third annual anniversary of the Grant Date, provided the Executive continues his employment through the vesting date. The PRSUs shall be subject to the same performance metrics as the Company's existing performance-based restricted stock units granted in 2024 and shall be memorialized in a Performance Restricted Stock Unit Agreement pursuant to the Company's 2023 Incentive Award Plan.
(d) Sign On Bonus. In addition to the Base Salary, in the event the Executive begins employment on the Start Date, the Executive will receive a one-time

“ sign on bonus in the amount of $100,000”,

less applicable taxes (the "Signing Bonus") to be paid in the first 30 days following the Start Date. If the Executive does not join the Company on the Start Date, the Executive will not receive the Signing Bonus.

[stocksrising]

It all comes down to terrible management that can’t get 10k / Q’s out on timely basis*!! Cash burn for C.Ste benefit vs. shareholders!!! CFO hopefully was fired bcuz he & auditors couldn’t get Leaseback properly journaled!!! Wall St/Analysts don’t trust CEO!!! Was never a believer in these ambulance chasers, but I will def join class action when contacted( via mail) …as for the 3 product FDA approval, I give mgmt A+ plus the payer successes…I will add once K’s/Q’s filed and figure out if CFO bailed ship due to Q2 financials are reported

[Moose412]

"bluebird has the largest and deepest ex-vivo gene therapy data set in the field".

This class action is dark times - but it's misplaced, and it will fail, with one of the defensible factors being the removal of "multiple undisclosed" from the pipeline page. That's not a pocket-ace for the sharks, if ya follow. I feel for those that lost, and I am down also - but this is solely on the FDA, and nobody's gonna sue them, sadly. All these sharks...trying to hold Bluebird accountable for ...forward-planning and a lack of caution by analysts?? Geez...the type-set was clear.

Pretty good buy action today, IMO. I've got a little left in the tank, and I see no reason to assume 30%+ share equity increase, but baking-in the value of 2500 therapy instances on 200m is a lot to wrap. Back to top, future...................unknown.

[stocksrising]

That implies a $6b takeout , from your lips to his ears! According to your price target, 300mm* shares @ $20=$6bills

*300m estimated shares outstanding after a couple rounds of equity raise(s)

Mgmt needs to have better cash burn controls, prefer RSU’s/grants vs. cash salaries( don’t care bout restrictive dilution, cash is king for micro’s)

[johnhancoque]

Gets bought above $20.00 within 18 months. No worries there imho

[Moose412]

Irrefutable...changed my mind, had to increase the position.

[Monksdream]

BLUE 10 day hourly chart

[Moose412]

You should post more. I have faith in Gina Wang's rating, and I also believe whether or not the first patient receiving Lyfgenia needs to have a second cell collection is going to be influential in significant ways.